Clarity Pharmaceuticals (ASX:CU6) OCF Margin %: 0.00% (As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.04
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals OCF Margin %?

Clarity Pharmaceuticals ASX:CU6 -3.32% 39 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Clarity Pharmaceuticals's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-47.79 Mil. Clarity Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Clarity Pharmaceuticals's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Clarity Pharmaceuticals's current OCF Yield % is -8.93%.

The historical rank and industry rank for Clarity Pharmaceuticals's OCF Margin % or its related term are showing as below:


ASX:CU6's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Clarity Pharmaceuticals OCF Margin % Related Terms

Clarity Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals OCF Margin % Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
OCF Margin %
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Clarity Pharmaceuticals's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-54.769/0
= %

Clarity Pharmaceuticals's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-47.794/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Clarity Pharmaceuticals (ASX:CU6) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Clarity Pharmaceuticals and its competitors. According to the industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 960 companies in the Biotechnology industry.
Is Clarity Pharmaceuticals' OCF Margin % too high?
Clarity Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, Clarity Pharmaceuticals ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 960 companies for OCF Margin %. This places Clarity Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.04
Price